Stock PTEC PRINCIPAL TECHNOLOGIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Principal Technologies Inc. Stock

Equities

PTEC

CA74260Q1028

Biotechnology & Medical Research

Delayed Toronto S.E.
Other stock markets
 11:00:00 2024-04-16 am EDT 		5-day change 1st Jan Change
0.15 CAD 0.00% Intraday chart for Principal Technologies Inc. 0.00% +11.11%
Apr. 03 Principal Technologies Announced Loan Financing and Private Placement and Updated On Vivostat A/S Acquisition MT
Apr. 03 Principal Technologies Inc. announced that it expects to receive CAD 1 million in funding CI

Financials

Sales 2022 0.34 0.47 Sales 2023 0.43 0.59 Capitalization 2.97M 4.09M
Net income 2022 -1M -1.37M Net income 2023 -1M -1.37M EV / Sales 2022 4,441,595 x
Net cash position 2022 276K 380K Net cash position 2023 81.08K 111K EV / Sales 2023 6,796,312 x
P/E ratio 2022
-1.32 x
P/E ratio 2023
-2.36 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 59.75%
More Fundamentals * Assessed data

Chart Principal Technologies Inc.

Dynamic Chart

Latest news about Principal Technologies Inc.

Principal Technologies Announced Loan Financing and Private Placement and Updated On Vivostat A/S Acquisition MT
Principal Technologies Inc. announced that it expects to receive CAD 1 million in funding CI
Principal Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 CI
Principal Technologies Acquiring Denmark's Vivostat for 7.5-Million Euros and 2.5-Million Shares MT
Principal Technologies Inc. entered into an arm's length binding share purchase agreement to acquire Vivostat A/S for ?7.8 million. CI
Principal Technologies Closes Third And Final Tranche Of Oversubscribed Private Placement MT
Principal Technologies Inc. announced that it has received CAD 1.498975 million in funding CI
Principal Technologies Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023 CI
Principal Technologies Completes 2nd Tranche; Upsizes Oversubscribed Private Placement MT
Principal Technologies Inc. Reports Earnings Results for the Full Year Ended July 31, 2023 CI
Principal Technologies Brief: Announced listing of Its Common Shares on the Frankfurt Stock Exchange MT
Toronto Stocks Flat; Denison Mines Rises on C$15 Million Investment in F3 Uranium DJ
Principal Technologies Inc. announced that it expects to receive CAD 0.9 million in funding CI
Principal Technologies Inc. announced that it has received CAD 0.301154 million in funding CI
Principal Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023 CI
More news

Press releases Principal Technologies Inc.

PRINCIPAL TECHNOLOGIES ANNOUNCES LOAN FINANCING AND PRIVATE PLACEMENT AND PROVIDES UPDATE ON VIVOSTAT A/S ACQUISITION AQ
PRINCIPAL TECHNOLOGIES ANNOUNCES FUNDAMENTAL ACQUISITION OF VIVOSTAT A/S AQ
Canadian Investment Regulatory Organization Trading Halt - PTEC AQ
PRINCIPAL TECHNOLOGIES CLOSES THIRD AND FINAL TRANCHE OF OVERSUBSCRIBED PRIVATE PLACEMENT AQ
PRINCIPAL TECHNOLOGIES CLOSES SECOND TRANCHE AND ANNOUNCES UPSIZE OF OVERSUBSCRIBED PRIVATE PLACEMENT AQ
More press releases

Quotes and Performance

3 months-6.25%
6 months+42.86%
Current year+11.11%
More quotes

Highs and lows

Current year
0.00
Extreme 0
0.17
1 year
0.00
Extreme 0
0.18
3 years
0.00
Extreme 0
0.25
5 years
0.00
Extreme 0
0.25
10 years
0.00
Extreme 0
0.25
More quotes

Managers and Directors - Principal Technologies Inc.

Managers TitleAgeSince
Gerald Trent CEO
 Chief Executive Officer 45 -
Peter L. McKeown DFI
 Director of Finance/CFO 68 23-03-05
Members of the board TitleAgeSince
Alfred von Liechtenstein BRD
 Director/Board Member 53 21-08-03
Leopold Specht BRD
 Director/Board Member 68 21-08-03
Gerald Trent CEO
 Chief Executive Officer 45 -
More insiders

Company Profile

Principal Technologies Inc. is a Canada-based company. The Company is engaged in building a diverse portfolio of investments in healthcare technology companies with a focus on those with global distribution potential which have intellectual property capable of enhancing medical treatment quality, cost efficiency, optimization of the patient pathway, and implementation of point of care technologies. It operates in one operational segment, being its operations in healthcare technology, including the project management of international scale clinical studies primarily related to medical device technologies. The Company's subsidiaries include Principal Technologies Capital Management GmbH and E&E CRO Consulting GmbH.
Sector
Biotechnology & Medical Research
Calendar
2024-06-24 - Q3 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PRINCIPAL TECHNOLOGIES INC. Stock Principal Technologies Inc.
+11.11% 3.61M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.66% 42.86B
MODERNA, INC. Stock Moderna, Inc.
+12.18% 42.74B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 41.36B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 27.68B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.89% 25.15B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.72% 18.63B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.21% 12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.39% 11.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.20% 11.21B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PTEC Stock